Ramzi M. Mohammad

7.7k citations

154 papers · 4.8k indexed · h-index 41

Impact in

Toxicology top 0.5%
- Bioactive Compounds and Antitumor Agents
Complementary and alternative medicine top 0.5%
- Nigella sativa pharmacological applications

Papers in

Toxicology 8
Genetics 20
- Chronic Lymphocytic Leukemia Research 20

Co-authors: Asfar S. Azmi Fazlul H. Sarkar Amro Aboukameel Ayad Al‐Katib Sanjeev Banerjee Philip A. Philip Irfana Muqbil Shahab Uddin
Journals: Cancers (9 papers)Cancer Research (8 papers)Molecular Cancer Therapeutics (7 papers)Journal of Clinical Oncology (6 papers)Blood (5 papers)
Partner nations: United States Qatar India

In The Last Decade

Ramzi M. Mohammad

151 papers receiving 4.7k citations

Peers

Countries citing papers authored by Ramzi M. Mohammad

Since Specialization

Citations

This map shows the geographic impact of Ramzi M. Mohammad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ramzi M. Mohammad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ramzi M. Mohammad more than expected).

Fields of papers citing papers by Ramzi M. Mohammad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ramzi M. Mohammad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ramzi M. Mohammad. The network helps show where Ramzi M. Mohammad may publish in the future.

Co-authors

The 25 scholars most cited alongside Ramzi M. Mohammad, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ramzi M. Mohammad Line = papers co-authored together Ramzi M. Mohammad links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	RCC1 regulation of subcellular protein localization via Ran GTPase drives pancreatic ductal adenocarcinoma growth Cancer Letters ·Sahar F. Bannoura, Amro Aboukameel, Husain Yar Khan, Md. Hafiz Uddin, Hyejeong Jang, Eliza W. Beal, Amalraj Thangasamy, Yang Shi, Seongho Kim, Kay‐Uwe Wagner, Rafic Beydoun, Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Muhammad Wasif Saif, Mohammed Najeeb Al Hallak, Boris Pasche, Asfar S. Azmi	2024	2
2	PAK4-NAMPT Dual Inhibition Sensitizes Pancreatic Neuroendocrine Tumors to Everolimus Molecular Cancer Therapeutics ·Gabriel Mpilla, Md. Hafiz Uddin, Mohammed Najeeb Al Hallak, Amro Aboukameel, Yiwei Li, Steve Kim, Rafic Beydoun, Gregory Dyson, Erkan Baloglu, William Senapedis, Yosef Landesman, Kay‐Uwe Wagner, Nerissa T. Viola, Bassel F. El‐Rayes, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	2021	16
3	Calcium Release-Activated Calcium (CRAC) Channel Inhibition Suppresses Pancreatic Ductal Adenocarcinoma Cell Proliferation and Patient-Derived Tumor Growth Cancers ·Husain Yar Khan, Gabriel Mpilla, Rachel Sexton, Srikant Viswanadha, Kumar V. Penmetsa, Amro Aboukameel, Maria Diab, Mandana Kamgar, Mohammed Najeeb Al Hallak, Mark Szlaczky, Anteneh Tesfaye, Steve Kim, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	2020	28
4	Preclinical Assessment with Clinical Validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the Treatment of Pancreatic Ductal Adenocarcinoma Clinical Cancer Research ·Asfar S. Azmi, Husain Yar Khan, Irfana Muqbil, Amro Aboukameel, Jasper E. Neggers, Dirk Daelemans, Amit Mahipal, Gregory Dyson, Mandana Kamgar, Mohammed Najeeb Al Hallak, Anteneh Tesfaye, Steve Kim, Vinod B. Shidham, Ramzi M. Mohammad, Philip A. Philip	2019	40
5	PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors Cancers ·Gabriel Mpilla, Amro Aboukameel, Irfana Muqbil, Steve Kim, Rafic Beydoun, Philip A. Philip, Ramzi M. Mohammad, Mandana Kamgar, Vinod B. Shidham, William Senapedis, Erkan Baloglu, Jing Li, Gregory Dyson, Yue Xue, Bassel F. El‐Rayes, Asfar S. Azmi	2019	24
6	Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance International Journal of Molecular Sciences ·Husain Yar Khan, James Ge, Misako Nagasaka, Amro Aboukameel, Gabriel Mpilla, Irfana Muqbil, Mark Szlaczky, Mahmoud Chaker, Erkan Baloglu, Yosef Landesman, Ramzi M. Mohammad, Asfar S. Azmi, Ammar Sukari	2019	30
7	The Replacement of five Consecutive Amino Acids in the Cyt1A Protein of Bacillus thuringiensis Enhances its Cytotoxic Activity against Lung Epithelial Cancer Cells Toxins ·Kavita Nair, Ahmad Iskandarani, Roda Al‐Thani, Ramzi M. Mohammad, Samir Jaoua	2018	3
8	Anticancer Activity of Camel Milk via Induction of Autophagic Death in Human Colorectal and Breast Cancer Cells Asian Pacific Journal of Cancer Prevention ·Roopesh Krishnankutty, Ahmad Iskandarani, Lubna Therachiyil, Shahab Uddin, Fouad Azizi, Michael B. Kulinski, Ajaz A. Bhat, Ramzi M. Mohammad	2018	47
9	Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma Molecular Cancer Therapeutics ·Amro Aboukameel, Irfana Muqbil, William Senapedis, Erkan Baloglu, Yosef Landesman, Sharon Shacham, Michael Kauffman, Philip A. Philip, Ramzi M. Mohammad, Asfar S. Azmi	2016	74
10	Bortezomib-mediated downregulation of S-phase kinase protein-2 (SKP2) causes apoptotic cell death in chronic myelogenous leukemia cells Journal of Translational Medicine ·Ahmad Iskandarani, Ajaz A. Bhat, Kodappully Sivaraman Siveen, Kirti S. Prabhu, Shilpa Kuttikrishnan, Muzammil Ahmad Khan, Roopesh Krishnankutty, Michał Kuliński, Rihab Nasr, Ramzi M. Mohammad, Shahab Uddin	2016	30
11	Involvement of F-BOX proteins in progression and development of human malignancies Seminars in Cancer Biology ·Shahab Uddin, Ajaz A. Bhat, Roopesh Krishnankutty, Fayaz Ahmad Mir, Michał Kuliński, Ramzi M. Mohammad	2015	44
12	A Novel Small-Molecule Inhibitor of Mcl-1 Blocks Pancreatic Cancer Growth In Vitro and In Vivo Molecular Cancer Therapeutics ·Fardokht A. Abulwerdi, Chenzhong Liao, Meilan Liu, Asfar S. Azmi, Amro Aboukameel, Ahmed S.A. Mady, Thippeswamy Gulappa, Tomasz Cierpicki, Scott R. Owens, Tao Zhang, Duxin Sun, Jeanne A. Stuckey, Ramzi M. Mohammad, Zaneta Nikolovska‐Coleska	2013	158
13	Proof of Concept: Network and Systems Biology Approaches Aid in the Discovery of Potent Anticancer Drug Combinations Molecular Cancer Therapeutics ·Asfar S. Azmi, Zhiwei Wang, Philip A. Philip, Ramzi M. Mohammad, Fazlul H. Sarkar	2010	76
14	MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy Oncogene ·Asfar S. Azmi, P. A. Philip, F W Beck, Zhiwei Wang, S. Banerjee, Shaomeng Wang, Dajun Yang, F. H. Sarkar, Ramzi M. Mohammad	2010	38
15	Structure-Activity Studies on Therapeutic Potential of Thymoquinone Analogs in Pancreatic Cancer Pharmaceutical Research ·Sanjeev Banerjee, Asfar S. Azmi, Subhash Padhyé, Marjit W. Singh, J.B. Baruah, Philip A. Philip, Fazlul H. Sarkar, Ramzi M. Mohammad	2010	75
16	Chemoprevention of Pancreatic Cancer: Characterization of Par-4 and its Modulation by 3,3′ Diindolylmethane (DIM) Pharmaceutical Research ·Asfar S. Azmi, Aamir Ahmad, Sanjeev Banerjee, Vivek M. Rangnekar, Ramzi M. Mohammad, Fazlul H. Sarkar	2008	46
17	A novel Bcl-2 small molecule inhibitor 4-(3-methoxy-phenylsulfannyl)-7-nitro-benzofurazan-3-oxide (MNB)-induced apoptosis in leukemia cells Annals of Hematology ·Manchao Zhang, Yan Ling, Chao‐Yie Yang, Hongpeng Liu, Renxiao Wang, Xihan Wu, Ke Ding, Feng Zhu, Brian Griffith, Ramzi M. Mohammad, Shaomeng Wang, Dajun Yang	2007	11
18	Flavones and polyphenols inhibit the NO pathway during apoptosis of leukemia B-cells Leukemia Research ·Claire Quiney, Daniel Dauzonne, Catherine Kern, Jean‐Dominique Fourneron, Jean‐Claude Izard, Ramzi M. Mohammad, Jean‐Pierre Kolb, Christian Billard	2004	51
19	Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. PubMed ·Ayad Al‐Katib, Mitchell R. Smith, W S Kamanda, George R. Pettit, Mohammed Hamdan, A.N. Mohamed, Bhadrani Chelladurai, Ramzi M. Mohammad	1998	58
20	Expression of a New Cellular Protein by Monocytoid B-Lymphocytes Differentiated from the Acute Lymphoblastic Leukemia Cell Line (REH) Leukemia & lymphoma ·Ramzi M. Mohammad, Carl R. Clark, Terry Maloney, Ben D.‐M. Chen, Ayad Al‐Katib	1991	4

About Ramzi M. Mohammad

Ramzi M. Mohammad is a scholar working on Toxicology, Genetics, Cancer Research, Oncology and Molecular Biology, having authored 154 papers that have together received 4.8k indexed citations. Recurring topics across this work include Cell death mechanisms and regulation (24 papers), Cancer-related Molecular Pathways (22 papers), Chronic Lymphocytic Leukemia Research (20 papers), Nuclear Structure and Function (17 papers), Lymphoma Diagnosis and Treatment (13 papers), Ubiquitin and proteasome pathways (12 papers), MicroRNA in disease regulation (11 papers) and RNA Research and Splicing (10 papers). The work is most often cited by research in Toxicology (336 citations), Complementary and alternative medicine (475 citations), Oncology (1.2k citations), Molecular Biology (2.9k citations) and Cancer Research (601 citations). Ramzi M. Mohammad has collaborated with scholars based in United States, Qatar and India. Frequent co-authors include Asfar S. Azmi, Fazlul H. Sarkar, Amro Aboukameel, Ayad Al‐Katib, Sanjeev Banerjee, Philip A. Philip, Irfana Muqbil, Shahab Uddin, Subhash Padhyé and Shaomeng Wang. Their work appears in journals such as Cancers, Cancer Research, Molecular Cancer Therapeutics, Journal of Clinical Oncology and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact